FR1525186A
(fr)
|
1967-03-29 |
1968-05-17 |
Roussel Uclaf |
Nouvelles pénicillines et procédé de préparation
|
EP0028489B1
(en)
|
1979-11-05 |
1983-10-05 |
Beecham Group Plc |
Enzyme derivatives, and their preparation
|
DE4034829A1
(de)
|
1990-11-02 |
1992-05-07 |
Merck Patent Gmbh |
Cyclopeptide
|
JP3190431B2
(ja)
|
1991-07-01 |
2001-07-23 |
三菱化学株式会社 |
ケトン誘導体
|
GB9206757D0
(en)
|
1992-03-27 |
1992-05-13 |
Ferring Bv |
Novel peptide receptor ligands
|
US5624936A
(en)
|
1995-03-29 |
1997-04-29 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
WO1996034010A2
(en)
|
1995-03-29 |
1996-10-31 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5869682A
(en)
|
1996-04-03 |
1999-02-09 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
JP2000507597A
(ja)
|
1996-04-03 |
2000-06-20 |
メルク エンド カンパニー インコーポレーテッド |
ファルネシルタンパク質トランスフェラーゼ阻害剤
|
PE121699A1
(es)
|
1997-02-18 |
1999-12-08 |
Boehringer Ingelheim Pharma |
Heterociclos biciclicos disustituidos como inhibidores de la trombina
|
ZA985247B
(en)
|
1997-06-19 |
1999-12-17 |
Du Pont Merck Pharma |
Guanidine mimics as factor Xa inhibitors.
|
TW557297B
(en)
|
1997-09-26 |
2003-10-11 |
Abbott Lab |
Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
|
GEP20043163B
(en)
|
1998-03-19 |
2004-01-26 |
Vertex Pharma |
Inhibitors of Caspases, Pharmaceutical Composition on its Base and Method for its Production
|
ES2310039T3
(es)
|
1998-05-26 |
2008-12-16 |
Warner-Lambert Company Llc |
Pirimidinas biciclicas y 3,4-dihidropirimidinas biciclicas como inhibidores de la proliferacion celular.
|
US6307049B1
(en)
|
1998-09-30 |
2001-10-23 |
The Procter & Gamble Co. |
Heterocyclic 2-substituted ketoamides
|
EP1016663A1
(en)
|
1999-01-02 |
2000-07-05 |
Aventis Pharma Deutschland GmbH |
Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor Xa activity)
|
KR20010101355A
(ko)
|
1999-01-02 |
2001-11-14 |
로버트 흐라이탁, 미쉘 베스트 |
신규한 말론산 유도체, 이의 제조 방법, 이의 용도 및이를 함유하는 약제학적 조성물(인자 xa 활성 억제)
|
TR200102913T2
(tr)
|
1999-04-09 |
2002-01-21 |
Basf Aktiengesellschaft |
Tam proteazların düşük moleküler ağırlıklı inhibitörleri.
|
CA2383008A1
(en)
|
1999-06-14 |
2000-12-21 |
Amanda Jane Lyons |
Compounds
|
DE19962924A1
(de)
|
1999-12-24 |
2001-07-05 |
Bayer Ag |
Substituierte Oxazolidinone und ihre Verwendung
|
EP1125925A1
(en)
|
2000-02-15 |
2001-08-22 |
Applied Research Systems ARS Holding N.V. |
Amine derivatives for the treatment of apoptosis
|
JP2004507456A
(ja)
|
2000-05-11 |
2004-03-11 |
ブリストル−マイヤーズ スクイブ カンパニー |
成長ホルモン分泌促進薬として有用なテトラヒドロイソキノリン類縁体
|
SV2003000617A
(es)
|
2000-08-31 |
2003-01-13 |
Lilly Co Eli |
Inhibidores de la proteasa peptidomimetica ref. x-14912m
|
AR035216A1
(es)
|
2000-12-01 |
2004-05-05 |
Astrazeneca Ab |
Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
|
AU2002322802A1
(en)
|
2001-07-27 |
2003-02-17 |
Merck And Co., Inc. |
Thrombin inhibitors
|
US6951840B2
(en)
|
2001-08-31 |
2005-10-04 |
Eli Lilly And Company |
Lipoglycopeptide antibiotics
|
PL204263B1
(pl)
|
2001-09-21 |
2009-12-31 |
Bristol Myers Squibb Co |
Pochodna 1H-pirazolo[3,4-c]pirydyny i jej zastosowanie oraz kompozycja farmaceutyczna i jej zastosowanie
|
US6649606B1
(en)
|
2001-11-09 |
2003-11-18 |
Bristol-Myers Squibb Co. |
Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
|
AU2002316317A1
(en)
|
2002-06-18 |
2003-12-31 |
The Scripps Research Institute |
Synthesis of diazonamide "a" core
|
US20040180855A1
(en)
|
2003-02-19 |
2004-09-16 |
Schumacher William A. |
Methods of treating thrombosis with reduced risk of increased bleeding times
|
US7138412B2
(en)
|
2003-03-11 |
2006-11-21 |
Bristol-Myers Squibb Company |
Tetrahydroquinoline derivatives useful as serine protease inhibitors
|
US7129264B2
(en)
|
2003-04-16 |
2006-10-31 |
Bristol-Myers Squibb Company |
Biarylmethyl indolines and indoles as antithromboembolic agents
|
EP1660439A2
(en)
|
2003-08-08 |
2006-05-31 |
Transtech Pharma, Inc. |
Aryl and heteroaryl compounds, compositions, and methods of use
|
US7417063B2
(en)
|
2004-04-13 |
2008-08-26 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles useful as serine protease inhibitors
|
US7429604B2
(en)
|
2004-06-15 |
2008-09-30 |
Bristol Myers Squibb Company |
Six-membered heterocycles useful as serine protease inhibitors
|
US7453002B2
(en)
|
2004-06-15 |
2008-11-18 |
Bristol-Myers Squibb Company |
Five-membered heterocycles useful as serine protease inhibitors
|
EP1773348A4
(en)
|
2004-07-12 |
2009-05-20 |
Idun Pharmaceuticals Inc |
TETRA PEPTIDE ANALOGS
|
JP5236293B2
(ja)
|
2005-01-13 |
2013-07-17 |
ブリストル−マイヤーズ スクイブ カンパニー |
Xia因子阻害剤としての置換ビアリール化合物
|
US20060183771A1
(en)
|
2005-02-17 |
2006-08-17 |
Seiffert Dietmar A |
Novel combination of selective factor VIIa and/or factor XIa inhibitors and selective plasma kallikrein inhibitors
|
US20070111947A1
(en)
|
2005-10-14 |
2007-05-17 |
Mcmurry Thomas J |
Fibrin targeted therapeutics
|
JP4955009B2
(ja)
|
2005-11-11 |
2012-06-20 |
エフ.ホフマン−ラ ロシュ アーゲー |
凝固因子Xaの阻害剤としての炭素環式縮合環アミン
|
NZ568595A
(en)
|
2005-12-14 |
2010-04-30 |
Bristol Myers Squibb Co |
Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor Xla inhibitors
|
CN101341124A
(zh)
|
2005-12-14 |
2009-01-07 |
布里斯托尔-迈尔斯斯奎布公司 |
可用作丝氨酸蛋白酶抑制剂的6元杂环
|
US8466295B2
(en)
|
2005-12-14 |
2013-06-18 |
Bristol-Myers Squibb Company |
Thiophene derivatives as factor XIa inhibitors
|
TW200745062A
(en)
|
2005-12-23 |
2007-12-16 |
Bristol Myers Squibb Co |
Macrocyclic factor VIIA inhibitors useful as anticoagulants
|
JP5342450B2
(ja)
|
2006-12-15 |
2013-11-13 |
ブリストル−マイヤーズ スクイブ カンパニー |
第XIa因子インヒビターとしてのアリールプロピオンアミド、アリールアクリルアミド、アリールプロピンアミド、またはアリールメチルウレアアナログ
|
PE20081775A1
(es)
|
2006-12-20 |
2008-12-18 |
Bristol Myers Squibb Co |
Compuestos macrociclicos como inhibidores del factor viia
|
EP2152664B1
(en)
|
2007-06-13 |
2014-09-03 |
Bristol-Myers Squibb Company |
Dipeptide analogs as coagulation factor inhibitors
|
ES2380648T3
(es)
|
2008-03-13 |
2012-05-17 |
Bristol-Myers Squibb Company |
Derivados de piridazina como inhibidores del factor XIA
|
US8624040B2
(en)
|
2009-06-22 |
2014-01-07 |
Millennium Pharmaceuticals, Inc. |
Substituted hydroxamic acids and uses thereof
|
WO2011002520A2
(en)
|
2009-07-02 |
2011-01-06 |
Angion Biomedica Corp. |
Small molecule inhibitors of parp activity
|
EP2462123B1
(en)
|
2009-08-04 |
2013-10-02 |
Merck Sharp & Dohme Corp. |
4,5,6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
|
EA020528B1
(ru)
*
|
2010-02-11 |
2014-11-28 |
Бристол-Майерс Сквибб Компани |
Макроциклы в качестве ингибиторов фактора xia
|
EP2729150B1
(en)
|
2011-07-08 |
2016-09-14 |
Merck Sharp & Dohme Corp. |
Factor ixa inhibitors
|
TW201319068A
(zh)
*
|
2011-08-05 |
2013-05-16 |
必治妥美雅史谷比公司 |
作為xia因子抑制劑之環狀p1接合劑
|
TW201311689A
(zh)
|
2011-08-05 |
2013-03-16 |
必治妥美雅史谷比公司 |
作為因子xia抑制劑之新穎巨環化合物
|
EP2766347B1
(en)
|
2011-10-14 |
2016-05-04 |
Bristol-Myers Squibb Company |
Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
|
ES2699226T3
(es)
|
2011-10-14 |
2019-02-08 |
Bristol Myers Squibb Co |
Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIa
|
RS56168B1
(sr)
|
2011-10-14 |
2017-11-30 |
Bristol Myers Squibb Co |
Supstituisana jedinjenja tetrahidroizohinolina kao inhibitori xia faktora
|
WO2013093484A1
(en)
|
2011-12-21 |
2013-06-27 |
Ono Pharmaceutical Co., Ltd. |
Pyridinone and pyrimidinone derivatives as factor xia inhibitors
|
GB2497806A
(en)
|
2011-12-21 |
2013-06-26 |
Ono Pharmaceutical Co |
Pyridinone and pyrimidinone derivatives as factor XIa inhibitors
|
US20140378474A1
(en)
|
2012-01-27 |
2014-12-25 |
Novartis Ag |
5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
|
US20140350034A1
(en)
|
2012-01-27 |
2014-11-27 |
Novartis Ag |
Aminopyridine derivatives as plasma kallikrein inhibitors
|
JP2015083542A
(ja)
|
2012-02-08 |
2015-04-30 |
大日本住友製薬株式会社 |
3位置換プロリン誘導体
|
DK2847228T3
(en)
|
2012-05-10 |
2018-11-19 |
Bayer Pharma AG |
ANTIBODIES THAT CAN BIND TO COAGULATION FACTOR XI AND / OR ITS ACTIVATED FORM FACTOR XIA, AND APPLICATIONS THEREOF
|
GB201209138D0
(en)
|
2012-05-24 |
2012-07-04 |
Ono Pharmaceutical Co |
Compounds
|
EP2876105A4
(en)
|
2012-07-19 |
2016-01-13 |
Sumitomo Dainippon Pharma Co Ltd |
1- (CYCLOALKYL-CARBONYL) PROLINE DERIVATIVE
|
DK2882734T3
(en)
*
|
2012-08-03 |
2017-01-30 |
Bristol Myers Squibb Co |
DIHYDROPYRIDON AS FACTOR-XIA INHIBITORS
|
HUE032622T2
(en)
*
|
2012-08-03 |
2017-10-30 |
Bristol Myers Squibb Co |
Dihydropyridone P1 as factor XIA inhibitors
|
LT2906551T
(lt)
|
2012-10-12 |
2018-04-25 |
Bristol-Myers Squibb Company |
Faktoriaus xia kristalinės formos
|
WO2014059202A1
(en)
|
2012-10-12 |
2014-04-17 |
Bristol-Myers Squibb Company |
Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
|
US9403774B2
(en)
|
2012-10-12 |
2016-08-02 |
Bristol-Myers Squibb Company |
Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
|
WO2014120346A1
(en)
|
2012-12-19 |
2014-08-07 |
Merck Sharp & Dohme Corp. |
Factor ixa inhibitors
|
GB201300304D0
(en)
|
2013-01-08 |
2013-02-20 |
Kalvista Pharmaceuticals Ltd |
Benzylamine derivatives
|
GB2510407A
(en)
|
2013-02-04 |
2014-08-06 |
Kalvista Pharmaceuticals Ltd |
Aqueous suspensions of kallikrein inhibitors for parenteral administration
|
ES2712699T3
(es)
|
2013-03-25 |
2019-05-14 |
Bristol Myers Squibb Co |
Tetrahidroisoquinolinas que contienen azoles sustituidos como inhibidores del factor XIa
|
TWI633089B
(zh)
|
2013-03-28 |
2018-08-21 |
拜耳製藥股份有限公司 |
經取代的酮基吡啶衍生物
|
WO2015011087A1
(de)
|
2013-07-23 |
2015-01-29 |
Bayer Pharma Aktiengesellschaft |
Substituierte oxopyridin-derivate und ihre verwendung als faktor xia / plasma
|
EP3049394A1
(de)
|
2013-09-26 |
2016-08-03 |
Bayer Pharma Aktiengesellschaft |
Substituierte phenylalanin-derivate als faktor xia modulatoren
|
EP3049410A1
(de)
|
2013-09-26 |
2016-08-03 |
Bayer Pharma Aktiengesellschaft |
Substituierte phenylalanin-derivate als faktor xia modulatoren
|
MA38925B1
(fr)
|
2013-09-26 |
2018-09-28 |
Bayer Pharma AG |
Dérivés de phénylalanine substitués
|
US20160280688A1
(en)
|
2013-09-26 |
2016-09-29 |
Bayer Pharma Aktiengesellschaft |
Substituted phenylalanine derivatives
|
EP3049406A1
(de)
|
2013-09-26 |
2016-08-03 |
Bayer Pharma Aktiengesellschaft |
Substituierte phenylalanin-derivate und ihre verwendung zur behandlung von thrombotischen / thromboembolischen erkrankungen
|
US20160280699A1
(en)
|
2013-09-26 |
2016-09-29 |
Bayer Pharma Aktiengesellschaft |
Substituted phenylalanine derivatives
|
TW201605828A
(zh)
|
2013-09-26 |
2016-02-16 |
拜耳製藥股份有限公司 |
經取代苯丙胺酸衍生物(三)
|
WO2015044169A1
(de)
|
2013-09-26 |
2015-04-02 |
Bayer Pharma Aktiengesellschaft |
Substituierte phenylalanin-derivate
|
WO2015047973A1
(en)
|
2013-09-27 |
2015-04-02 |
Merck Sharp & Dohme Corp. |
FACTOR XIa INHIBITORS
|
US20160257668A1
(en)
|
2013-10-07 |
2016-09-08 |
Merck Sharp & Dohme Corp. |
Factor XIa Inhibitors
|
JP6337750B2
(ja)
|
2013-11-22 |
2018-06-06 |
小野薬品工業株式会社 |
化合物
|
US9718840B2
(en)
|
2014-01-14 |
2017-08-01 |
Sumitomo Dainippon Pharma Co., Ltd. |
Condensed 5-oxazolidinone derivative
|
NO2760821T3
(pt)
|
2014-01-31 |
2018-03-10 |
|
|
EP3392249B1
(en)
|
2014-01-31 |
2021-08-25 |
Bristol-Myers Squibb Company |
Macrocycles with heterocyclic p2' groups as factor xia inhibitors
|
FI3102200T3
(fi)
|
2014-02-07 |
2023-05-31 |
Exithera Pharmaceuticals Inc |
Terapeuttisia yhdisteitä ja koostumuksia
|
WO2015123093A1
(en)
|
2014-02-11 |
2015-08-20 |
Merck Sharp & Dohme Corp. |
Factor xia inhibitors
|
US9663527B2
(en)
|
2014-02-11 |
2017-05-30 |
Merck Sharp & Dohme Corp. |
Factor XIa inhibitors
|
WO2015123091A1
(en)
|
2014-02-11 |
2015-08-20 |
Merck Sharp & Dohme Corp. |
Factor xia inhibitors
|
CN105829298B
(zh)
|
2014-02-14 |
2019-02-01 |
四川海思科制药有限公司 |
一种吡啶酮或嘧啶酮衍生物、及其制备方法和应用
|
CN106257976B
(zh)
|
2014-03-07 |
2021-02-02 |
拜奥克里斯特制药公司 |
人类血浆激肽释放酶抑制剂
|
EP3131897B8
(en)
|
2014-04-16 |
2022-08-03 |
Merck Sharp & Dohme LLC |
Factor ixa inhibitors
|
EP3131896B1
(en)
|
2014-04-16 |
2019-01-30 |
Merck Sharp & Dohme Corp. |
Factor ixa inhibitors
|
KR20150136294A
(ko)
|
2014-05-27 |
2015-12-07 |
주식회사 레고켐 바이오사이언스 |
인자 XIa 억제 활성을 가지는 신규한 화합물
|
AU2015267305A1
(en)
|
2014-05-28 |
2016-11-03 |
Merck Sharp And Dohme Corp. |
Factor XIa inhibitors
|
ES2712886T3
(es)
|
2014-09-24 |
2019-05-16 |
Bayer Pharma AG |
Derivados de piridobenzazepina y piridobenzazocina que inhiben el factor XIa
|
NO2721243T3
(pt)
|
2014-10-01 |
2018-10-20 |
|
|
US9453018B2
(en)
|
2014-10-01 |
2016-09-27 |
Bristol-Myers Squibb Company |
Pyrimidinones as factor XIa inhibitors
|
WO2016093285A1
(ja)
|
2014-12-10 |
2016-06-16 |
小野薬品工業株式会社 |
ジヒドロインドリジノン誘導体
|
WO2016205482A1
(en)
|
2015-06-19 |
2016-12-22 |
Bristol-Myers Squibb Company |
Diamide macrocycles as factor xia inhibitors
|